Literature DB >> 19440082

Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.

Rhee-Hun Kang1, Sun-Min Jung, Kyoung-Ah Kim, Duk-Ki Lee, Hyun-Kee Cho, Bong-Joo Jung, Young-Ku Kim, Seung-Hyun Kim, Changsu Han, Min-Soo Lee, Ji-Young Park.   

Abstract

This study was conducted to evaluate the effects of the CYP2D6 and CYP3A5 genotypes on the steady-state plasma levels of risperidone (RIS), 9-hydroxyrisperidone (9-OH-RIS), and the active moiety (RIS plus 9-OH-RIS) in Korean schizophrenic patients. Sixty-four Korean schizophrenic patients were enrolled. CYP2D6 and CYP3A5 genotypes were determined, and the plasma levels of RIS and 9-OH-RIS were measured using high-performance liquid chromatography. The dose-normalized plasma concentrations of RIS, 9-OH-RIS, and the active moiety were compared according to the CYP2D6 and CYP3A5 genotypes. Among the patients, 57 were CYP2D6 extensive metabolizers (EMs; CYP2D6*1/*1, *1/*10, and *10/*10) and 7 were CYP2D6 poor metabolizers (PMs; CYP2D6*1/*5 and *10/*5). For the CYP3A5 genotype, 30 patients were CYP3A5*1 expressors (*1/*1 [n = 1] and *1/*3 [n = 29]) and 34 patients were CYP3A5 nonexpressors (*3/*3). The plasma levels of RIS (2.03 ng/mL per milligram for EMs vs 5.57 ng/mL per milligram for PMs, P < 0.001) and 9-OH-RIS (5.06 ng/mL per milligram for EMs vs 0.22 ng/mL per milligram for PMs, P < 0.001) were significantly different among CYP2D6 genotype groups, but the CYP2D6 EMs (7.09 ng/mL per milligram) and PMs (5.79 ng/mL per milligram) did not show no difference in the levels of the active moiety (P = 0.470). CYP3A5 nonexpressors exhibited higher plasma concentrations of both RIS and 9-OH-RIS than its expressors. In the case of 9-OH-RIS, CYP3A5 nonexpressors exhibited significantly higher concentrations than CYP3A5 expressors (5.42 vs 3.51 ng/mL per milligram, P = 0.022). In addition, concentrations of the active moiety were also significantly different between the CYP3A5 nonexpressors (8.39 ng/mL per milligram) and expressors (5.30 ng/mL per milligram, P = 0.005). In conclusion, both CYP2D6 and CYP3A5 genotypes affected plasma levels of RIS and 9-OH-RIS, whereas the active moiety levels were influenced only by the CYP3A5 genotype but not by the CYP2D6 genotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19440082     DOI: 10.1097/JCP.0b013e3181a289e0

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  12 in total

1.  Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.

Authors:  Hee-Doo Yoo; Hea-Young Cho; Sang-No Lee; Hwa Yoon; Yong-Bok Lee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-05-24       Impact factor: 2.745

2.  Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10.

Authors:  Hee-Doo Yoo; Sang-No Lee; Hyun-Ah Kang; Hea-Young Cho; Il-Kwon Lee; Yong-Bok Lee
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

3.  Development of a complex parent-metabolite joint population pharmacokinetic model.

Authors:  Julie Bertrand; Céline M Laffont; France Mentré; Marylore Chenel; Emmanuelle Comets
Journal:  AAPS J       Date:  2011-05-27       Impact factor: 4.009

4.  Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.

Authors:  Frederik Vandenberghe; Monia Guidi; Eva Choong; Armin von Gunten; Philippe Conus; Chantal Csajka; Chin B Eap
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

Review 5.  Genomics and pharmacogenomics of schizophrenia.

Authors:  Ramón Cacabelos; Rocío Martínez-Bouza
Journal:  CNS Neurosci Ther       Date:  2010-08-16       Impact factor: 5.243

6.  Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis.

Authors:  Qi Pei; Lu Huang; Jie Huang; Jing-Kai Gu; Yun Kuang; Xiao-Cong Zuo; Jun-Jie Ding; Hong-Yi Tan; Cheng-Xian Guo; Shi-Kun Liu; Guo-Ping Yang
Journal:  Acta Pharmacol Sin       Date:  2016-09-26       Impact factor: 6.150

7.  Development and Validation of Liquid Chromatography/Tandem Mass Spectrometry Analysis for Therapeutic Drug Monitoring of Risperidone and 9-Hydroxyrisperidone in Pediatric Patients with Autism Spectrum Disorders.

Authors:  Natchaya Vanwong; Santirat Prommas; Apichaya Puangpetch; Yaowaluck Hongkaew; Nopadol Nuntamool; Chalitpol Na Nakorn; Nattawat Ngamsamut; Penkhae Limsila; Chonlaphat Sukasem
Journal:  J Clin Lab Anal       Date:  2016-06-26       Impact factor: 2.352

8.  ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.

Authors:  Hee-Jun Kim; Seock-Ah Im; Bhumsuk Keam; Hye Seon Ham; Kyung Hun Lee; Tae Yong Kim; Yu Jung Kim; Do-Youn Oh; Jee Hyun Kim; Wonshik Han; In-Jin Jang; Tae-You Kim; In Ae Park; Dong Young Noh
Journal:  Cancer Sci       Date:  2014-12-08       Impact factor: 6.716

9.  Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone.

Authors:  Yaowaluck Hongkaew; Andrea Gaedigk; Bob Wilffert; Nattawat Ngamsamut; Wiranpat Kittitharaphan; Penkhae Limsila; Chonlaphat Sukasem
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

10.  Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort.

Authors:  Tyren M Dodgen; Arinda Eloff; Connie Mataboge; Louw J L Roos; Werdie C W van Staden; Michael S Pepper
Journal:  Appl Transl Genom       Date:  2015-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.